APOL2

Across TCGA pan-cancer cohorts, APOL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APOL2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher APOL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APOL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

GBM, UCEC, and CCRCC are the cancer types where APOL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.277	0.475	.003	24	view →
UCEC	OS	Median	III,IV	1.000	0.494	.016	14	view →
CCRCC	DFS	Tertile	III,IV	0.474	0.805	.019	7	view →
COAD	DFS	Quartile	III,IV	0.791	1.000	.049	6	view →
LUAD	DFS	Tertile	III,IV	0.825	0.365	.031	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APOL2–GBM (DFS)

Open the GBM breakdown →